Europe Rapid Acting Insulin Market By Product Type (Insulin Lispro, Insulin Aspart and Insulin Glulisine), By Indication (Type 2 Diabetes and Type 1 Diabetes), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers), By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the Europe Rapid Acting Insulin Market
Market Report Description
The Europe Rapid Acting Insulin Market would witness market growth of 5.2% CAGR during the forecast period (2021-2027). Rapid-acting insulins come in the form which can be easily absorbed by the body, without the need to break it down. With regular insulin, the body does the work of decreasing the insulin protein to a small size before it is ready for absorption and starts activating. The regular insulin can consume above 30 minutes from the time it is injected until it starts activating on cells. With rapid-acting insulins, this time becomes half, so there is less possibility of mistakes. It starts activating in a similar manner as naturally produced insulin does.
Insulin resistance is associated with a higher rate of blood pressure and coronary heart disorders. In multiple clinical trials on individuals with heart failure, the infusion of insulin, potassium, and glucose enhanced heart pumping function. Insulin compels the relaxation of muscles in the artery walls, hence accelerating blood flow. Various human studies revealed higher blood flow levels in the heart muscle after insulin administration. In a cell-based study, insulin improved the production and secretion of a compound which is essential for the creation of new blood vessels. Therefore, these positive outcomes of insulin would boost the demand for rapid-acting insulin in the upcoming years.
The Germany market dominated the Europe Type 1 Diabetes Market by Country in 2020, thereby, achieving a market value of $92.2 Million by 2027. The UK market is exhibiting a CAGR of 5.1% during (2021 - 2027). Additionally, The France market is poised to grow at a CAGR of 7.4% during (2021 - 2027).
Based on Product Type, the market is segmented into Insulin Lispro, Insulin Aspart and Insulin Glulisine. Based on Indication, the market is segmented into Type 2 Diabetes and Type 1 Diabetes. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Providers. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Rapid Acting Insulin Market Size will Hit $11.4 Billion by 2027, at a CAGR of 5.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck & Co., Inc., Sanofi S.A., Novo Nordisk A/S, Eli Lilly and Company, Adocia SA, Biocon Limited, Gan & Lee Pharmaceuticals, Geropharm LLC, Wockhardt Ltd., and MannKind Corporation.
Scope of the Study
Market Segments Covered in the Report:
By Product Type
- Insulin Lispro
- Insulin Aspart
- Insulin Glulisine
- Type 2 Diabetes
- Type 1 Diabetes
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Providers
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Merck & Co., Inc.
- Sanofi S.A.
- Novo Nordisk A/S
- Eli Lilly and Company
- Adocia SA
- Biocon Limited
- Gan & Lee Pharmaceuticals
- Geropharm LLC
- Wockhardt Ltd.
- MannKind Corporation
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free